LO FRANCIS sold $695K of ADPT

LO FRANCIS (Chief People Officer) sold 39,741 shares of Adaptive Biotechnologies Corp (ADPT) at $17.49 ($0.70M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LO FRANCIS
Published Jun 9, 2026, 12:29 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The only new fact is the officer’s open-market sale amount, share count, and confirmation of a pre-arranged 10b5-1 plan; no new company fundamentals are disclosed.

02

Market read

A routine 10b5-1 insider sale (~$695K) is disclosed; it is unlikely to materially change ADPT’s valuation absent other catalysts.

03

What to watch

The article lacks context on whether this is part of a larger selling cadence, and it provides no linkage to company-specific news.

Relevance 4/10Novelty 2/10Timing: Filed June 8; sale dated June 4

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Adaptive Biotechnologies insider Form 4 shows Chief People Officer LO FRANCIS sold 39,741 shares for ~$695K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived and sentiment-driven.

Evidence & confidence

The disclosure is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory/financial catalyst in the text.

Market effects

No clear read-across to biotech sector fundamentals from a single officer 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with periods of weaker outlook; traders may watch for follow-on sales or other insider actions.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the SEC Form 4 insider transaction disclosure.

  • LO FRANCIS

    Chief People Officer who sold 39,741 ADPT shares.

  • 10b5-1 plan

    Pre-arranged plan indicated as the basis for the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.